Industry
Drug Manufacturers - Specialty & Generic
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Loading...
Open
13.76
Mkt cap
44B
Volume
839K
High
13.86
P/E Ratio
22.97
52-wk high
15.08
Low
13.72
Div yield
0.05
52-wk low
12.58
Portfolio Pulse from Benzinga Newsdesk
September 14, 2023 | 12:11 pm
Portfolio Pulse from Vandana Singh
September 13, 2023 | 5:55 pm
Portfolio Pulse from Benzinga Newsdesk
September 13, 2023 | 2:02 pm
Portfolio Pulse from Bill Haddad
September 13, 2023 | 12:01 pm
Portfolio Pulse from Benzinga Newsdesk
September 12, 2023 | 1:46 pm
Portfolio Pulse from Benzinga Newsdesk
September 11, 2023 | 10:50 am
Portfolio Pulse from Benzinga Insights
September 08, 2023 | 8:30 pm
Portfolio Pulse from Nabaparna Bhattacharya
August 28, 2023 | 12:22 pm
Portfolio Pulse from Benzinga Newsdesk
August 28, 2023 | 10:33 am
Portfolio Pulse from Benzinga Insights
August 17, 2023 | 7:00 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.